Abstract | AIMS: The normal expression of Ca(2+)-regulatory protein is critical for efficient myocardial function. The present study tested the hypothesis that rosuvastatin treatment may attenuate left ventricular (LV) remodelling and dysfunction in the failing heart, which may be associated with alterations of Ca(2+)-regulatory protein. METHODS AND RESULTS: CONCLUSION:
Rosuvastatin is effective in preventing LV remodelling and dysfunction in the failing heart. The molecular mechanism may be related to normalization of SERCA2a expression, SERCA activity, and pSer16-PLB levels, as well as through cytokine alterations independent of its lipid-lowering effect.
|
Authors | Ying Yang, Yun Mou, Shen-Jiang Hu, Michael Fu |
Journal | European journal of heart failure
(Eur J Heart Fail)
Vol. 11
Issue 1
Pg. 6-13
(Jan 2009)
ISSN: 1388-9842 [Print] England |
PMID | 19147451
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Calcium-Binding Proteins
- Fluorobenzenes
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Interleukin-6
- Pyrimidines
- Sulfonamides
- phospholamban
- Interleukin-10
- Rosuvastatin Calcium
- Sarcoplasmic Reticulum Calcium-Transporting ATPases
- Atp2a2 protein, mouse
|
Topics |
- Animals
- Calcium-Binding Proteins
(drug effects, metabolism)
- Disease Models, Animal
- Fluorobenzenes
(pharmacology)
- Heart
(physiopathology)
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(pharmacology)
- Interleukin-10
(blood)
- Interleukin-6
(blood)
- Male
- Organ Size
(drug effects)
- Pyrimidines
(pharmacology)
- Rats
- Rats, Sprague-Dawley
- Rosuvastatin Calcium
- Sarcoplasmic Reticulum Calcium-Transporting ATPases
(drug effects, metabolism)
- Sulfonamides
(pharmacology)
- Ventricular Remodeling
(drug effects)
|